Cargando…

The AHEAD 3–45 Study: Design of a prevention trial for Alzheimer’s disease

INTRODUCTION: The Alzheimer’s disease (AD) continuum begins with a long asymptomatic or preclinical stage, during which amyloid beta (Aβ) is accumulating for more than a decade prior to widespread cortical tauopathy, neurodegeneration, and manifestation of clinical symptoms. The AHEAD 3–45 Study (BA...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rafii, Michael S., Sperling, Reisa A., Donohue, Michael C., Zhou, Jin, Roberts, Claire, Irizarry, Michael C., Dhadda, Shobha, Sethuraman, Gopalan, Kramer, Lynn D, Swanson, Chad J, Li, David, Krause, Stephen, Rissman, Robert A., Walter, Sarah, Raman, Rema, Johnson, Keith A., Aisen, Paul S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9929028/ https://www.ncbi.nlm.nih.gov/pubmed/35971310 http://dx.doi.org/10.1002/alz.12748

Ejemplares similares

Consistency of efficacy results across various clinical measures and statistical methods in the lecanemab phase 2 trial of early Alzheimer’s disease
por: Dhadda, Shobha, et al.
Publicado: (2022)

Lecanemab for Patients With Early Alzheimer Disease: Bayesian Analysis of a Phase 2b Dose-Finding Randomized Clinical Trial
por: Berry, Donald A., et al.
Publicado: (2023)

ARIA in patients treated with lecanemab (BAN2401) in a phase 2 study in early Alzheimer's disease
por: Honig, Lawrence S., et al.
Publicado: (2023)

Peripheral and central effects of γ-secretase inhibition by semagacestat in Alzheimer’s disease
por: Doody, Rachelle S, et al.
Publicado: (2015)

The Trial-Ready Cohort for Preclinical/Prodromal Alzheimer’s Disease (TRC-PAD) Project: An Overview
por: Aisen, P.S., et al.
Publicado: (2020)

Predicting amyloid risk by machine learning algorithms based on the A4 screen data: Application to the Japanese Trial‐Ready Cohort study
por: Sato, Kenichiro, et al.
Publicado: (2021)

Lecanemab in patients with early Alzheimer’s disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study
por: McDade, Eric, et al.
Publicado: (2022)

Early-stage Alzheimer disease: getting trial-ready
por: Aisen, Paul S., et al.
Publicado: (2022)

The down syndrome biomarker initiative (DSBI) pilot: proof of concept for deep phenotyping of Alzheimer’s disease biomarkers in down syndrome
por: Rafii, Michael S., et al.
Publicado: (2015)

Cross-validation of optimized composites for preclinical Alzheimer's disease
por: Donohue, Michael C., et al.
Publicado: (2016)

Safety and tolerability of lumbar puncture for the evaluation of Alzheimer's disease
por: Baldaranov, Dobri, et al.
Publicado: (2023)

Instrumental activities of daily living, amyloid, and cognition in cognitively normal older adults screening for the A4 Study
por: Marshall, Gad A., et al.
Publicado: (2020)

Feasibility study for detection of retinal amyloid in clinical trials: The Anti‐Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) trial
por: Ngolab, Jennifer, et al.
Publicado: (2021)

TRC-PAD: Accelerating Recruitment of AD Clinical Trials through Innovative Information Technology
por: Jimenez-Maggiora, G.A., et al.
Publicado: (2020)

Disparities by Race and Ethnicity Among Adults Recruited for a Preclinical Alzheimer Disease Trial
por: Raman, Rema, et al.
Publicado: (2021)

Effect of AZD0530 on Cerebral Metabolic Decline in Alzheimer Disease: A Randomized Clinical Trial
por: van Dyck, Christopher H., et al.
Publicado: (2019)

Bayesian latent time joint mixed-effects model of progression in the Alzheimer's Disease Neuroimaging Initiative
por: Li, Dan, et al.
Publicado: (2018)

Predicting the course of Alzheimer’s progression
por: Iddi, Samuel, et al.
Publicado: (2019)

Intranasal insulin modulates cerebrospinal fluid markers of neuroinflammation in mild cognitive impairment and Alzheimer’s disease: a randomized trial
por: Kellar, Derek, et al.
Publicado: (2022)

The A4 study: β‐amyloid and cognition in 4432 cognitively unimpaired adults
por: Insel, Philip S., et al.
Publicado: (2020)

Design of a Bayesian adaptive phase 2 proof-of-concept trial for BAN2401, a putative disease-modifying monoclonal antibody for the treatment of Alzheimer's disease
por: Satlin, Andrew, et al.
Publicado: (2016)

Recent developments in Alzheimer's disease therapeutics
por: Rafii, Michael S, et al.
Publicado: (2009)

Advances in Alzheimer’s Disease Drug Development
por: Rafii, Michael S, et al.
Publicado: (2015)

Predicting Amyloid Burden to Accelerate Recruitment of Secondary Prevention Clinical Trials
por: Langford, O., et al.
Publicado: (2020)

A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease
por: Turner, R. Scott, et al.
Publicado: (2015)

Impact of sex and APOE ε4 on the association of cognition and hippocampal volume in clinically normal, amyloid positive adults
por: Petersen, Kellen K., et al.
Publicado: (2022)

Centralizing prescreening data collection to inform data-driven approaches to clinical trial recruitment
por: Kirn, Dylan R., et al.
Publicado: (2023)

Large-Scale Functional Brain Network Abnormalities in Alzheimer’s Disease: Insights from Functional Neuroimaging
por: Dickerson, Bradford C., et al.
Publicado: (2009)

Meaningful benefits: a framework to assess disease-modifying therapies in preclinical and early Alzheimer’s disease
por: Assunção, Sheila Seleri, et al.
Publicado: (2022)

Intranasal Insulin Reduces White Matter Hyperintensity Progression in Association with Improvements in Cognition and CSF Biomarker Profiles in Mild Cognitive Impairment and Alzheimer’s Disease
por: Kellar, D., et al.
Publicado: (2021)

Brain amyloid burden, sleep, and 24-hour rest/activity rhythms: screening findings from the Anti-Amyloid Treatment in Asymptomatic Alzheimer’s and Longitudinal Evaluation of Amyloid Risk and Neurodegeneration Studies
por: Spira, Adam P, et al.
Publicado: (2021)

Tackling a Major Deficiency of Diversity in Alzheimer’s Disease Therapeutic Trials: An CTAD Task Force Report
por: Raman, Rema, et al.
Publicado: (2022)

A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody
por: Swanson, Chad J., et al.
Publicado: (2021)

Correction to: A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody
por: Swanson, Chad J., et al.
Publicado: (2022)

The Trial-Ready Cohort for Preclinical and Prodromal Alzheimer’s Disease (TRC-PAD): Experience from the First 3 Years
por: Walter, S., et al.
Publicado: (2020)

Functional MRI Assessment of Task-Induced Deactivation of the Default Mode Network in Alzheimer’s Disease and At-Risk Older Individuals
por: Pihlajamäki, Maija, et al.
Publicado: (2009)

Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease
por: Bateman, Randall J, et al.
Publicado: (2011)

The relative efficiency of time-to-progression and continuous measures of cognition in presymptomatic Alzheimer's disease
por: Li, Dan, et al.
Publicado: (2019)

Neuroanatomical spread of amyloid β and tau in Alzheimer’s disease: implications for primary prevention
por: Insel, Philip S, et al.
Publicado: (2020)

Associations of Stages of Objective Memory Impairment With Amyloid PET and Structural MRI: The A4 Study
por: Grober, Ellen, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_av7gkfaajd2ut37oi03on00vsh